PTI News and Press, Yumanity Therapeutics Inc Com From 06/05/19

InflaRx N.V. (NASDAQ: IFRX )  -87%  after IFX-1 flunks mid-stage study. More news on: InflaRx N.V., GameStop Corp., ChemoCentryx, Inc., Stocks on the move, Read more ...

PTI stock is moving higher in Tuesday’s session following the news that Proteostasis Therapeutics Inc (NASDAQ:PTI) received orphan drug designation in the EU for PTI-428, its treatment for cystic fibrosis. Orphan Drug Designation Boston, Massachusetts-based Proteostasis Therapeut...

Castor Maritime (NASDAQ: CTRM ) +112%  on 1H results . More news on: Castor Maritime Inc., Attis Industries, Inc., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...

The European Commission (EC) has granted orphan drug designation to Proteostasis Therapeutics' (NASDAQ: PTI ) PTI-428 for the treatment of cystic fibrosis. More news on: Proteostasis Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

BOSTON , June 4, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing...

BOSTON , June 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein p...

BOSTON , May 15, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein proc...

BOSTON , May 13, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing...

BOSTON , May 8, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein proce...

After staging a rally from the start of 2019, Vertex ( VRTX ) has experienced some price setback as a result of a cut in the revenue forecasts from analysts, as pushback against pricing of its products in the UK and EU rage on. Here is the outlook for VRTX as we head towards the start of the s...